{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:19:25Z","timestamp":1771460365694,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020141","name":"Akebia Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004323","name":"Amylin Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017243","name":"Michigan Diabetes Research Center, University of Michigan","doi-asserted-by":"publisher","award":["P60DK020572"],"award-info":[{"award-number":["P60DK020572"]}],"id":[{"id":"10.13039\/100017243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000433"],"award-info":[{"award-number":["UL1TR000433"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018242","name":"Michigan Nutrition Obesity Research Center, Medical School, University of Michigan","doi-asserted-by":"publisher","award":["P 30DK089503"],"award-info":[{"award-number":["P 30DK089503"]}],"id":[{"id":"10.13039\/100018242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.medj.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T11:04:43Z","timestamp":1620817483000},"page":"814-835.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings"],"prefix":"10.1016","volume":"2","author":[{"given":"Baris","family":"Akinci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Subauste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Ajluni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazanene H.","family":"Esfandiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-5049","authenticated-orcid":false,"given":"Rasimcan","family":"Meral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam H.","family":"Neidert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akin","family":"Eraslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Hench","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Rus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mckenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hero K.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1476-4274","authenticated-orcid":false,"given":"Thomas L.","family":"Chenevert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan K.","family":"Tayeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit R.","family":"Rupani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari S.","family":"Conjeevaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Burant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-1144","authenticated-orcid":false,"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2021.04.001_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/ceh.2018.78120","article-title":"A systematic review of the present and future of non-alcoholic fatty liver disease","volume":"4","author":"Lucas","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"key":"10.1016\/j.medj.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"178","author":"Lazo","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.medj.2021.04.001_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.medj.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medj.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.22009","article-title":"Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach","volume":"47","author":"Bellentani","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2021.04.001_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"e74558","DOI":"10.1371\/journal.pone.0074558","article-title":"Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?","volume":"8","author":"Bjelakovic","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medj.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.medj.2021.04.001_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin\u2019s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon","year":"2013","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.medj.2021.04.001_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2021.04.001_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.medj.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/bioinformatics\/btn592","article-title":"LRpath: a logistic regression approach for identifying enriched biological groups in gene expression data","volume":"25","author":"Sartor","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.medj.2021.04.001_bib20","doi-asserted-by":"crossref","first-page":"49066","DOI":"10.1074\/jbc.M107250200","article-title":"Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob\/ob mouse liver","volume":"276","author":"Liang","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.medj.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.medj.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort","volume":"86","author":"Ajluni","year":"2017","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.medj.2021.04.001_bib23","first-page":"EDM190139","article-title":"The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide","volume":"2020","author":"Akinci","year":"2020","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.medj.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","article-title":"NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk","volume":"34","author":"Ballestri","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.medj.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The clinical approach to the detection of lipodystrophy\u2014an AACE consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.medj.2021.04.001_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2021.04.001_bib28","doi-asserted-by":"crossref","DOI":"10.2337\/db18-296-LB","article-title":"Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults with Low Leptin Levels","volume":"67","author":"Depaoli","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.medj.2021.04.001_bib29","first-page":"109","article-title":"Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans","volume":"16","author":"Fogteloo","year":"2003","journal-title":"Diabetes Nutr. Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jcem.85.11.6955","article-title":"Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men","volume":"85","author":"Hukshorn","year":"2000","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/db10-1791","article-title":"Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance","volume":"60","author":"Moon","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.medj.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.medj.2021.04.001_bib33","first-page":"305","article-title":"Gender-Based Differences in Leptinemia in Healthy Aging, Non-obese Individuals Associate with Increased Marker of Oxidative Stress","volume":"1","author":"Agrawal","year":"2008","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.medj.2021.04.001_bib34","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1172\/JCI81860","article-title":"Adipocyte iron regulates leptin and food intake","volume":"125","author":"Gao","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2021.04.001_bib35","doi-asserted-by":"crossref","first-page":"e23813","DOI":"10.7554\/eLife.23813","article-title":"Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression","volume":"6","author":"Rocha","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.medj.2021.04.001_bib36","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4161\/adip.20574","article-title":"New insights into adipocyte-specific leptin gene expression","volume":"1","author":"Wrann","year":"2012","journal-title":"Adipocyte"},{"key":"10.1016\/j.medj.2021.04.001_bib37","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1074\/mcp.RA118.000961","article-title":"Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits","volume":"17","author":"Lee","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.medj.2021.04.001_bib38","doi-asserted-by":"crossref","first-page":"35464","DOI":"10.1074\/jbc.M801011200","article-title":"COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression","volume":"283","author":"Kato","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.medj.2021.04.001_bib39","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1123374","article-title":"TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism","volume":"312","author":"Qi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.medj.2021.04.001_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.29273","article-title":"The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation","volume":"66","author":"BasuRay","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2021.04.001_bib41","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1172\/JCI89344","article-title":"Olfactory receptor 544 reduces adiposity by steering fuel preference toward fats","volume":"127","author":"Wu","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2021.04.001_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-018-0002-3","article-title":"Therapeutic potential of ectopic olfactory and taste receptors","volume":"18","author":"Lee","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2021.04.001_bib43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI200419511","article-title":"Site and mechanism of leptin action in a rodent form of congenital lipodystrophy","volume":"113","author":"Asilmaz","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2021.04.001_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.medj.2021.04.001_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3803\/EnM.2017.32.1.6","article-title":"The SCAP\/SREBP Pathway: A Mediator of Hepatic Steatosis","volume":"32","author":"Moon","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.medj.2021.04.001_bib46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/MOL.0b013e3282f9b54d","article-title":"Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism","volume":"19","author":"Flowers","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.medj.2021.04.001_bib47","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.bbalip.2016.07.012","article-title":"SCD1 deficiency protects mice against ethanol-induced liver injury","volume":"1861","author":"Lounis","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.medj.2021.04.001_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3402\/ijch.v69i4.17669","article-title":"Individual saturated fatty acids are associated with different components of insulin resistance and glucose metabolism: the GOCADAN study","volume":"69","author":"Ebbesson","year":"2010","journal-title":"Int. J. Circumpolar Health"},{"key":"10.1016\/j.medj.2021.04.001_bib49","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00125-009-1282-2","article-title":"Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations","volume":"52","author":"Kotronen","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.medj.2021.04.001_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.diabres.2009.11.019","article-title":"Serum fatty acid composition and insulin resistance are independently associated with liver fat markers in elderly men","volume":"87","author":"Petersson","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.medj.2021.04.001_bib51","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1111\/j.1440-1746.2007.04961.x","article-title":"Role of adipocytokines in hepatic fibrogenesis","volume":"22","author":"Ikejima","year":"2007","journal-title":"J.\u00a0Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2021.04.001_bib52","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1096\/fj.04-1847fje","article-title":"Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation","volume":"18","author":"Saxena","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.medj.2021.04.001_bib53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-8278(02)00414-2","article-title":"Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration","volume":"38","author":"Potter","year":"2003","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.medj.2021.04.001_bib54","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/jhep.2002.32029","article-title":"Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob\/ob mice","volume":"35","author":"Saxena","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2021.04.001_bib55","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI8341","article-title":"Pathophysiological role of leptin in obesity-related hypertension","volume":"105","author":"Aizawa-Abe","year":"2000","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2021.04.001_bib56","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cell.2014.10.058","article-title":"Leptin mediates the increase in blood pressure associated with obesity","volume":"159","author":"Simonds","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.04.001_bib57","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2015.07.007","article-title":"Leptin Does Not Mediate Hypertension Associated With Human Obesity","volume":"162","author":"Brown","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.medj.2021.04.001_bib58","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.medj.2021.04.001_bib59","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2016-3628","article-title":"Effects of Metreleptin in Pediatric Patients With Lipodystrophy","volume":"102","author":"Brown","year":"2017","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.medj.2021.04.001_bib61","series-title":"Myalept prescribing information","year":"2015"},{"key":"10.1016\/j.medj.2021.04.001_bib62","series-title":"Myalepta","year":"2018"},{"key":"10.1016\/j.medj.2021.04.001_bib63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.medj.2021.04.001_bib64","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4158\/EP09155.RA","article-title":"Rationale for leptin-replacement therapy for severe lipodystrophy","volume":"16","author":"Oral","year":"2010","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.medj.2021.04.001_bib65","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.medj.2021.04.001_bib66","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.medj.2021.04.001_bib67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.medj.2021.04.001_bib68","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib69","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety","volume":"97","author":"Simha","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib70","doi-asserted-by":"crossref","first-page":"137180","DOI":"10.1172\/jci.insight.137180","article-title":"Leptin decreases de novo lipogenesis in patients with lipodystrophy","volume":"5","author":"Baykal","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.medj.2021.04.001_bib71","first-page":"659","article-title":"Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J.\u00a0Diabetes Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib72","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0026-0495(97)90222-5","article-title":"Relationship between resting metabolic rate and the composition of the fat-free mass","volume":"46","author":"Sparti","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.medj.2021.04.001_bib73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1475-097X.1991.tb00662.x","article-title":"Validation of body composition by dual energy X-ray absorptiometry (DEXA)","volume":"11","author":"Haarbo","year":"1991","journal-title":"Clin. Physiol."},{"key":"10.1016\/j.medj.2021.04.001_bib74","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2337\/dc18-0978","article-title":"\u201cFat Shadows\u201d From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers","volume":"41","author":"Meral","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medj.2021.04.001_bib75","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2021.04.001_bib76","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can. J. Biochem. Physiol."},{"key":"10.1016\/j.medj.2021.04.001_bib77","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ekir.2016.08.007","article-title":"Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort","volume":"1","author":"Afshinnia","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.medj.2021.04.001_bib78","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2337\/db14-0509","article-title":"Metabolomics and diabetes: analytical and computational approaches","volume":"64","author":"Sas","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.medj.2021.04.001_bib79","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1021\/ac901143w","article-title":"Compensation for systematic cross-contribution improves normalization of mass spectrometry based metabolomics data","volume":"81","author":"Redestig","year":"2009","journal-title":"Anal. Chem."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634021001501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634021001501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:54:35Z","timestamp":1763002475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634021001501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2666634021001501"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2021.04.001","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}